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Abstract
Objectives: Gallbladder carcinoma (GBC) is a rare disease that is often diagnosed incidentally in its early
stages. Simple cholecystectomy is considered the standard treatment for stage I GBC. This study was
conducted in a large cohort of patients with stage I GBC to test the hypothesis that the extent of surgery
affects survival.
Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database
was queried to identify patients in whom microscopically confirmed, localized (stage I) GBC was diag-
nosed between 1988 and 2008. Surgical treatment was categorized as cholecystectomy alone, chole-
cystectomy with lymph node dissection (C + LN) or radical cholecystectomy (RC). Age, gender, race,
ethnicity, T1 sub-stage [T1a, T1b, T1NOS (T1 not otherwise specified)], radiation treatment, extent of
surgery, cause of death and survival were assessed by log-rank and Cox's regression analyses.
Results: Of 2788 patients with localized GBC, 1115 (40.0%) had pathologically confirmed T1a, T1b or
T1NOS cancer. At a median follow-up of 22 months, 288 (25.8%) had died of GBC. Five-year survival
rates associated with cholecystectomy, C + LN and RC were 50%, 70% and 79%, respectively (P <
0.001). Multivariate analysis showed that surgical treatment and younger age were predictive of improved
disease-specific survival (P < 0.001), whereas radiation therapy portended worse survival (P = 0.013).
Conclusions: In the largest series of patients with stage I GBC to be reported, survival was significantly
impacted by the extent of surgery (LN dissection and RC). Cholecystectomy alone is inadequate in stage
I GBC and its use as standard treatment should be reconsidered.
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Introduction
An estimated 9810 new cases of gallbladder carcinoma (GBC)
were diagnosed in the USA in 2011, resulting in 3200 deaths.1
Outcomes in patients with regional GBC improve after the resec-
tion of liver segments IVb and V and the dissection of periportal
lymph nodes (LNs).2–6 This approach has been recommended for
patients with tumour extending into the liver (tumour stage T2 or
higher).2–5 By contrast, GBC confined to the lamina propria (T1a)
or to the muscularis propria (T1b) has historically been treated
with cholecystectomy alone and very small studies have reported
good results.7,8 Most patients with localized GBC are diagnosed
incidentally after routine laparoscopic cholecystectomy.2,9,10
Despite evidence for the adverse prognostic impact of LN metas-
tases, the need for further surgery in these patients remains
controversial.5,11–15
Current staging of GBC follows the standard tumour–node–
metastasis (TNM) system (Table 1) and reflects progressively
worse survival with increasing stage.16 This study reports the
largest population-based analysis of outcomes of stage I GBC
patients in the USA by demographic, treatment and survival
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characteristics. This study was conducted to test the hypothesis
that patients in whom surgical treatment included LN dissection
or radical cholecystectomy (RC) would survive longer than
patients treated with cholecystectomy alone.
Materials and methods
The National Cancer Institute (NCI) Surveillance, Epidemiology
and End Results (SEER) registry is a government-run database
that collects population-based data from 14 regional and three
supplemental cancer registries, which together represent approxi-
mately 26% of the population in the USA.17 Data held in the SEER
registry contain no identifiers and are publicly available for studies
of cancer-based epidemiology and health policy, and thus are
exempt from institutional review board approval requirements.
The NCI’s SEER*Stat software was used to identify patients in
whom microscopically confirmed, invasive, localized, node-
negative GBC was diagnosed between 1988 and 2008.18 A 98%
case ascertainment is mandated with annual quality assurance
studies.17 Only patients with stage I [T1a, T1b, T1NOS (not oth-
erwise specified)] GBC were included. Patients were excluded if
they had in situ or T2 or worse disease as determined by the extent
of disease codes. Patients were also excluded if surgical treatment
included locally ablative treatment, biopsy only or surgery not
otherwise specified. Age, sex, race, ethnicity, T1 sub-stage, tumour
grade, tumour histology, radiation treatment, extent of surgery,
cause of death, survival in months and vital status were assessed.
Chemotherapy data are not included in the SEER database.
Surgical treatment in the SEER database is categorized as com-
prising: simple cholecystectomy with no LNs recovered per extent
of disease coding; cholecystectomy with any LN recovery reported
in the extent of disease coding (C + LN); RC including any type of
liver resection with extensive LN dissection, and surgery not oth-
erwise specified (other). Data on staged resections are not avail-
able in the SEER database. Patients were assigned to one of three
outcome categories: dead from GBC; dead from other causes, and
alive at the end of the study.
Statistics
Summary statistics and Kaplan–Meier survival curves were gen-
erated using SAS Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
P-values for survival curves were determined by the log-rank test.
Cox’s proportional hazard regression analysis was performed
incorporating variables with P < 0.1 on the log-rank test and the
final model was built utilizing a stepwise selection method.
Results
Of 2788 patients with localized GBC, 300 (10.8%) and 536 (19.2%)
had microscopically confirmed T1a or T1b disease, respectively,
and 279 (10.0%) had T1NOS disease (Table 2). Female and White
patients were more commonly represented. Thus, of these 1115
localized tumours, 300 (26.9%) represented T1a, 536 (48.1%)
represented T1b and the remaining 279 (25.0%) represented
T1NOS disease. Tumour size in those patients in whom it was
reported was evenly distributed; however, tumour size was not
reported in 942 (84.5%) patients. Of the 1115 patients with stage I
GBC, 892 (80.0%) patients underwent cholecystectomy, only 168
(15.1%) underwent C + LN and 55 (4.9%) underwent RC. Only 97
(8.7%) patients received adjuvant radiation therapy.
Of the 1115 patients with stage I GBC, 421 (37.7%) were alive at
the end of the study. The 694 deaths (62.2%) included 288
Table 1 American Joint Committee on Cancer staging for gallbladder cancer16
Stage TNM Depth Regional lymph node status Distant
metastases
0 Tis In situ None None
Ia T1aN0M0 <Lamina propria None None
Ib T1bN0M0 <Muscular layer None None
II T2N0M0 <Perimuscular tissue; no extension beyond
serosa or into liver
None None
IIIa T3N0M0 >Serosa and/or directly invades the liver and/or
other adjacent organ or structure
None None
IIIb T1-3N1M0 Any Positive nodes along cystic duct bile, common bile
duct, hepatic artery and/or portal vein
None
IVa T4N0M0 Invades main portal vein, hepatic artery or >2
extrahepatic organs/structures
None None
T2N1M0 < Perimuscular tissue; no extension beyond
serosa or into liver
Positive nodes along cystic duct bile, common bile
duct, hepatic artery and/or portal vein
None
IVb T1-3N2M0 Any Positive nodes: peri-aortic, pericaval, superior
mesenteric artery and/or coeliac artery lymph
nodes
None
T1-3N1-2 M1 Any Any Yes
TNM, tumour–node–metastasis; Tis, tumour in situ.
HPB 41
HPB 2013, 15, 40–48 © 2012 International Hepato-Pancreato-Biliary Association
(41.5%) from GBC, 127 (18.3%) from other types of cancer, 133
(19.2%) from heart or vascular disease, eight (1.2%) from neuro-
logical disease, 21 (3.0%) from infection, 26 (3.7%) from lung
disease, 11 (1.6%) from accident or suicide, 35 (5.0%) from other
causes, and 45 (6.5%) from unknown causes. Median follow-up
was 22 months (range: 7–244 months).
The type of surgery selected varied slightly by tumour stage,
although the differences did not reach statistical significance
(Fig. 1). Patients with T1a and T1b disease were equally likely to
undergo cholecystectomy alone [n = 236 (78.7%) vs. n = 42
(79.7%); P = 0.731], C + LN [n = 54 (18.0%) vs. n = 79 (14.7%);
P = 0.258] or RC [n = 10 (3.3%) vs. n = 30 (5.6%); P = 0.055].
Based on univariate analysis, sex, race and tumour size had no
significant effect on 5-year disease-specific survival (DSS) in
patients with T1 GBC (Table 2). Younger age (P < 0.001), T1a
disease (P < 0.001) and examination of one or more LNs (P =
0.001) were associated with better DSS. Race was not a contribut-
ing factor (P = 0.934). Rates of DSS were also significantly higher
after C + LN (70%) or RC (79%) than after cholecystectomy alone
(50%) (P < 0.001) (Fig. 2). Disease-specific survival was shorter in
patients who received radiation therapy.
Five-year overall survival (OS) was not significantly affected
by sex, tumour size or radiation therapy (Table 2). As might be
expected, younger patients had significantly better survival than
older patients (P < 0.001). Asians and Pacific Islanders with GBC
achieved better survival than African-American and White
patients (47% vs. 29%, respectively; P = 0.017). Similar to DSS, OS
in patients with T1a disease was superior to that in those with T1b
disease (54% and 39%, respectively; P < 0.001). Overall survival
was significantly affected by the extent of surgery (Fig. 3). Patients
who underwent C + LN or RC achieved better survival (53% and
48%, respectively) than patients treated with cholecystectomy
alone (35%) (P < 0.001).
Further investigation regarding the role of surgical therapy
based on T1 sub-stage revealed no DSS advantage in T1a patients
who underwent more extensive surgery (C + LN or RC) compared
with patients treated with cholecystectomy alone (Fig. 4a).
However, T1b patients did benefit from more extensive surgery
Table 2 Demographic and survival data for patients with stage I gallbladder carcinoma
Variable Patients, n (%) 5-year survival
DSS, % OS, %
Age, years
<50 85 (7.6) 80% 68%
50–59 141 (12.6) 63% 55%
60–69 214 (19.2) 56% 49%
70–79 329 (29.5) 53% 37%
80 346 (31.1) 42% 20%
P < 0.001 P < 0.001
Gender
Female 846 (75.9) 54% 39%
Male 269 (24.1) 55% 37%
P = 0.725 P = 0.560
Race
White 881 (79.0) 53% 38%
African-American 90 (8.1) 50% 29%
Asian/Other 144 (12.9) 64% 47%
P = 0.093 P = 0.017
Tumour stage I sub-stage
T1NOS 279 (25.0) 34% 22%
T1a 300 (26.9) 70% 54%
T1b 536 (48.1) 56% 39%
P < 0.001 P < 0.001
Tumour size, cm
Unknown 942 (84.5) 52% 37%
<1.0 44 (4.0) 87% 72%
1.1–2.0 30 (2.7) 51% 37%
2.1–3.0 36 (3.2) 80% 58%
3.1–4.0 27 (2.4) 46% 40%
>4.0 36 (3.2) 67% 55%
P = 0.394 P = 0.553
Variable Patients, n (%) 5-year survival
DSS, % OS, %
Tumour grade
Well differentiated 264 (23.7) 68% 49%
Moderately differentiated 409 (36.7) 56% 40%
Poorly differentiated 197 (17.7) 26% 15%
Undifferentiated 19 (1.7) 21% 21%
Unknown 226 (20.3) 62% 46%
P < 0.001 P < 0.001
Tumour histology
Adenocarcinoma 881 (79.0) 51% 36%
Neuroendocrine 21 (1.9) 95% 81%
Papillary 141 (12.6) 76% 46%
Other 72 (6.5) 30% 25%
P < 0.001 P < 0.001
Surgery type
Cholecystectomy 892 (80.0) 50% 35%
C + LN 168 (15.1) 70% 53%
RC 55 (4.9) 79% 48%
P < 0.001 P < 0.001
Lymph nodes examined, n
Unknown 23 (2.1) 62% 50%
0 855 (76.7) 51% 35%
1–4 213 (19.1) 65% 49%
>5 24 (2.2) 63% 56%
P = 0.001 P < 0.001
Radiation therapy
No 1004 (90.4) 56% 39%
Yes 97 (8.4) 33% 28%
Unknown 14 (1.2) 48% 48%
P < 0.005 P < 0.087
DSS, disease-specific survival; OS, overall survival; T1NOS, tumour stage I not otherwise specified; C + LN, cholecystectomy plus lymph node
dissection; RC, radical cholecystectomy.
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(Fig. 4b). These findings correlate with OS patterns in T1a and
T1b patients (Fig. 5).
A multivariate Cox proportional hazard survival model was
built using a stepwise selection method incorporating age, race,
tumour sub-stage, tumour grade, tumour histology, radiation
therapy and surgery type. Independent predictors for DSS were
age, T1 sub-stage, tumour grade, tumour histology, radiation and
surgery type. Independent predictors for OS were age, T1
sub-stage, tumour grade, tumour histology, race and surgery type.
Table 3 gives the results of a Cox proportional hazard regression
model in the entire stage I GBC cohort based on 5-year DSS and
OS. Patients who underwent C + LN and RC had a significant
DSS benefit over patients who underwent cholecystectomy alone
[hazard ratio (HR) 0.501, 95% confidence interval (CI) 0.353–
0.710 (P = 0.001) and HR 0.410, 95% CI 0.218–0.814 (P = 0.006),
respectively].
Figure 1 Types of surgery performed in tumour stage I (T1) gallbladder carcinoma. Green bars, radical cholecystectomy; blue bars,
cholecystectomy plus lymph node resection; purple bars, cholecystectomy only; T1NOS, T1 not otherwise specified
Figure 2 Kaplan–Meier curves for disease-specific survival in
patients with tumour stage I (T1) gallbladder carcinoma by type of
surgery (P < 0.0001). C + LN, cholecystectomy plus lymph node
resection; RC, radical cholecystectomy
Figure 3 Kaplan–Meier curves for overall survival in patients with
tumour stage I (T1) gallbladder carcinoma by type of surgery (P <
0.0001). C + LN, cholecystectomy plus lymph node resection;
RC, radical cholecystectomy
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Discussion
The standard of care in the surgical treatment of GBC remains
controversial. Current recommended therapy for early GBC
includes cholecystectomy for T1a tumours, and cholecystectomy
with liver resection and periportal, gastrohepatic and retroduode-
nal LN dissection for T1b tumours.19 In this population-based
cohort, 46.0% of patients with stage I GBC treated with cholecys-
tectomy eventually died of GBC. By contrast, the risk for death
from GBC appeared to significantly decrease when the operative
procedure included the resection of any LNs and liver resection.
Although this study found that most patients with T1b GBC
received cholecystectomy alone, their survival differed signifi-
cantly from that of patients with T1a or T1NOS disease. This may
reflect the understaging of nodal disease in the absence of nodal
sampling.
Nodal status is the most powerful predictor of outcomes in
patients with stage I GBC.12,20,21 These data indicated improved
survival when cholecystectomy was accompanied by LN resection
(C + LN or RC). Although the results of Cox regression analysis
demonstrated the prognostic importance of age in patients with
stage I GBC, the improved survival associated with the examina-
tion of any LNs suggests a staging issue. This may be attributed to
a stage migration phenomenon in which the better detection of
disease results in more accurate staging.
Ogura et al.5 studied a multi-hospital cohort of 1686 Japanese
patients who underwent radical resections for GBC. Of 201
patients with mucosal involvement only (T1a), 2.5% had LN
metastases; of 165 patients in whom disease involved the muscu-
laris propria (T1b), 15.6% had metastases in local LNs. Had
these patients undergone cholecystectomy alone, their disease
would have been staged strictly on the basis of the primary
tumour. This highlights the distinction between primary tumour
(T) stage, which is based on the depth (not size) of the initial
lesion, and cancer stage, which incorporates nodal and metastatic
components.
In order to adequately assess LN status, the guidelines of the
American Joint Committee on Cancer (AJCC) require the
removal and pathologic examination of at least three regional
LNs, which can include cystic, pericholedochal, retroportal,
Figure 4 Kaplan–Meier curves for disease-specific survival in patients with (a) tumour stage Ia (T1a) (P = 0.614) and (b) tumour stage Ib (T1b)
(P = 0.0002) gallbladder carcinoma, by type of surgery. C + LN, cholecystectomy plus lymph node resection; RC, radical cholecystectomy
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periduodenal, peripancreatic, coeliac and superior mesenteric
nodes.16 Given that a majority of stage I GBC patients receive only
cholecystectomy (77.0% in this cohort), this suggests that the
majority of patients with stage I GBC may have been inadequately
staged.
Shirai et al.22 used intra-lymphatic injection of indigo carmine
to map the drainage pattern of gallbladder lymphatics in 21
patients with biliary tract cancer. The blue dye traced a path
around the bile ducts, through the cystic LN, into the pericholedo-
chal LNs and then into the retroportal and peripancreatic LNs.
Others have examined the frequency of GBC nodal metastases by
nodal basin. These studies indicate that the cystic and peric-
holedochal LNs are the most common sites of initial tumour
spread.3,11,12
At the time of diagnosis, advanced GBC is likely to have spread
to locoregional sites. As a result, chemotherapy is indicated,
particularly when a negative margin (R0) resection is not
achievable.23–27 However, the data are limited in advanced GBC
and even more scant in stage I GBC. The role of adjuvant radia-
tion in GBC also remains unclear.28 In this study, radiation therapy
had a negative impact on survival. However, radiation therapy was
applied in a limited number of patients and as all radiation was
given postoperatively, radiation therapy may have been reserved
for use in patients with a higher risk for recurrence.
No prospective trial has examined the impact of nodal surgery
on outcomes in patients with stage I GBC. Most of the studies
published during the last 21 years have been small, single-
institution series with relatively short follow-up (Table 4). Given
the infrequency of GBC and the rarity of its diagnosis in its earliest
stages, the small numbers of patients in these studies is not sur-
prising. Several studies have reported 5-year survival rates of
100%, but most of these included only two to 40 patients at
selected institutions.3,4,9,11,29,30 To the authors’ knowledge, the
present study represents the largest population-based investiga-
tion of outcomes in patients with stage I GBC.
Although the use of the population-based SEER dataset mini-
mized the risk for selection bias associated with smaller studies,
the enormous size of the SEER database inevitably limits its detail
on specific surgical and oncologic management. In addition, the
SEER database was not designed to include data on comorbidities,
Figure 5 Kaplan–Meier curves for overall survival in patients with (a) tumour stage Ia (T1a) (P = 0.9314) and (b) tumour stage Ib (T1b)
(P = 0.0172) gallbladder carcinoma. C + LN, cholecystectomy plus lymph node resection; RC, radical cholecystectomy
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Table 3 Adjusted Cox proportional hazards regression model for 5-year disease-specific survival (DSS) and overall survival (OS) in patients
with stage I gallbladder carcinoma
Variable: reference Variables: comparison 5-year disease-specific survival 5-year overall survival
HR (95% CI) P-value HR (95% CI) P-value
Age: <50 years 50–59 years 1.628 (0.889–2.981) 0.114 1.260 (0.771–2.059) 0.357
60–69 years 1.922 (1.084–3.408) 0.025 1.501 (0.947–2.379) 0.084
70–79 years 1.923 (1.102–3.355) 0.021 1.951 (1.256–3.031) 0.003
>80 years 2.608 (1.496–4.548) 0.001 3.023 (1.949–4.687) <0.001
Race: White Black N/A N/A 1.629 (1.236–2.148) <0.005
Other N/A N/A 0.888 (0.688–1.144) 0.357
Unknown N/A N/A 0.000 (0.000–0.000) 0.956
T1 sub-stage: T1a T1b 1.311 (0.989–1.739) 0.060 1.240 (0.994–1.547) 0.057
T1NOS 2.470 (1.845–3.307) <0.001 1.931 (1.524–2.448) <0.001
Surgery type: cholecystectomy alone C + LN 0.501 (0.353–0.710) 0.001 0.638 (0.488–0.834) 0.001
RC 0.410 (0.218–0.771) 0.006 0.742 (0.490–1.122) 0.157
Grade: well differentiated Moderate 1.483 (1.104–1.991) 0.009 1.239 (0.985–1.558) 0.067
Poor 2.696 (1.977–3.675) <0.001 2.107 (1.642–2.704) <0.001
Undifferentiated 3.430 (1.885–6.242) <0.001 2.233 (1.259–3.963) 0.006
Unknown 1.193 (0.843–1.688) 0.318 1.048 (0.798–1.375) 0.737
Histology: adenocarcinoma Neuroendocrine 0.129 (0.018–0.933) 0.043 0.316 (0.116–0.865) 0.025
Papillary 0.505 (0.338–0.756) <0.009 0.594 (0.440–0.803) <0.001
Other 1.997 (1.431–2.789) <0.001 1.734 (1.279–2.350) <0.004
HR, hazard ratio; 95% CI, 95% confidence interval; N/A, not available; T1NOS, tumour stage I not otherwise specified; C + LN, cholecystectomy plus
lymph node dissection; RC, radical cholecystectomy.
Table 4 Clinical studies of patients with stage I gallbladder carcinoma published in the last 21 years
Authors, year Patients, n Overall survival Comment/treatment
Median, months 5 years, % 10 years, %
Wibbenmeyer et al., 199531 2 16a
Yamaguchi et al., 199632 2 Not mentioned 100% at 2 years
Mingoli et al., 199733 2 6.5
Kraas et al., 20029 2 100%a
Arnaud et al., 199529 4 100%
Shimada et al., 19973 4 100% RC
Donohue et al., 19904 6 100% Cholecystectomy, RC
Sarli et al., 200034 6 24a Cholecystectomy
Gall et al., 199135 7 100 57%
North et al., 199836 7 24
Whalen et al., 200137 11 19.5
Kang et al., 200738 11 Not mentioned Cholecystectomy
Tsukada et al., 199711 15 76 91% RC
Sun et al., 200530 15 100% Cholecystectomy
Cho et al., 201014 18 Not mentioned Cholecystectomy
de Aretxabala et al., 199739 24 87.50% Cholecystectomy, RC
Suzuki et al., 20008 25 96% Cholecystectomy
Wakai et al., 20017 25 90–95 87% T1b/cholecsytectomy, RC
Chan et al., 200640 33 87% Cholecystectomy
Shirai et al., 199210 40 100% Cholecystectomy, RC
Goetze & Paolucci, 201015 118 56 49–71% Cholecystectomy, RC
Ogura et al., 19915 366 78% RC
Downing et al., 201112 683 33–93 Cholecystectomy, C + LN, RC
aApproximate.
C + LN, cholecystectomy plus lymph node dissection; RC, radical cholecystectomy.
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which may be problematic in studies of elderly populations.
Finally, in this study, 44.2% of patients were found to have died
from unknown causes.
Because staging based strictly on the primary tumour may be
inadequate in some patients with GBC, the present authors rec-
ommend that a combination of cholecystectomy and periportal or
more extensive LN dissection be used when the patient’s medical
condition permits nodal staging of GBC. More accurate assess-
ment of nodal status should improve the assessment of prognosis
and thereby guide the selection of patients for clinical trials and
for more rigorous follow-up.
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